Managing CNS involvement in systemic lupus erythematosus

International Journal of Clinical Rheumatology

Volumn 6, Issue 5, 2011, Pages 547-567

  Piga, Matteo ^a   Mathieu, Alessandro ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

antiphospholipid antibodies; cerebral MRI; cerebral vasculopathy; CNS; epdiemiology; neuroimaging; neuropsychiatric manifestations; pathogenesis; SLE serology; systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHOSPHOLIPID ANTIBODY; PREDNISONE; RITUXIMAB; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ACUTE CONFUSION; ACUTE PSYCHOSIS; ASEPTIC MENINGITIS; BLEEDING; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; CRANIAL NEUROPATHY; CYTOKINE PRODUCTION; DEMYELINATING DISEASE; DIFFUSION WEIGHTED IMAGING; DRUG MEGADOSE; HEADACHE; HUMAN; LOW DRUG DOSE; MYELITIS; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPSYCHIATRIC MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PLASMAPHERESIS; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; REVIEW; RISK FACTOR; SEIZURE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINAL CORD DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; THROMBOSIS PREVENTION;

EID: 80053527219     PISSN: 17584272     EISSN: 17584280     Source Type: Journal    
DOI: 10.2217/ijr.11.44     Document Type: Review

References (136)

1. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 42, 599-608 (1999).
2. Hanly JG, Mccurdy G, Fougere L, Douglas JA, Thompson K. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J. Rheumatol. 31, 2156-2162 (2004). (Pubitemid 39453234)
3. Sanna G, Bertolaccini ML, Cuadrado MJ et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J. Rheumatol. 30, 985-992 (2003). (Pubitemid 36529618)
4. Afeltra A, Garzia P, Mitterhofer AP et al. Neuropsychiatric lupus syndromes: relationship with antiphospholipid antibodies. Neurology 61, 108-110 (2003). (Pubitemid 36818758)
5. Brey RL, Holliday SL, Saklad AR et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 58, 1214-1220 (2002). (Pubitemid 34411865)
6. Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 57, 496-500 (2001). (Pubitemid 32757599)
7. Sibbitt WL Jr, Brandt JR, Johnson CR et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J. Rheumatol. 29, 1536-1542 (2002). (Pubitemid 34755624)
8. Hanly JG, Urowitz MB, Sanchez-Guerrero J et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 56, 265-273 (2007). (Pubitemid 46106200)
9. Ainiala H, Hietaharju A, Loukkola J et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum. 45, 419-423 (2001). (Pubitemid 32979846)
10. Hanly JG, Urowitz MB, Su L et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 69, 529-535 (2010).
11. Jennekens FG, Kater L. The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology (Oxford) 41, 605-618 (2002). (Pubitemid 34618878)
12. Davey R, Bamford J, Emery P. The ACR classification criteria for headache disorders in SLE fail to classify certain prevalent headache types. Cephalalgia 28, 296-299 (2008). (Pubitemid 351172033)
13. Rowshani AT, Remans P, Rozemuller A, Tak PP. Cerebral vasculitis as a primary manifestation of systemic lupus erythematosus. Ann. Rheum. Dis. 64, 784-786 (2005). (Pubitemid 40559313)
14. Jennekens FG, Kater L. The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation. Rheumatology (Oxford) 41, 619-630 (2002). (Pubitemid 34618879)
15. Scolding NJ, Joseph FG. The neuropathology and pathogenesis of systemic lupus erythematosus. Neuropathol. Appl. Neurobiol. 28, 173-189 (2002). (Pubitemid 34639440)
16. Sastre-Garriga J, Montalban X. APS and the brain. Lupus 12, 877-882 (2003). (Pubitemid 38082081)
17. Colasanti T, Delunardo F, Margutti P et al. Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus. J. Neuroimmunol. 212, 3-9 (2009).
18. Trysberg E, Nylen K, Rosengren LE, Tarkowski A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum. 48, 2881-2887 (2003). (Pubitemid 37280617)
19. Sanna G, Piga M, Terryberry JW et al. Central nervous system involvement in systemic lupus erythematosus: cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations. Lupus 9, 573-583 (2000).
20. Lu XY, Chen XX, Huang LD, Zhu CQ, Gu YY, Ye S. Anti-a-internexin autoantibody from neuropsychiatric lupus induce cognitive damage via inhibiting axonal elongation and promote neuron apoptosis. PLoS ONE 5, e11124 (2010).
21. Sanna G, Bertolaccini ML, Cuadrado MJ, Khamashta MA, Hughes GR. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology (Oxford) 42, 200-213 (2003). (Pubitemid 36305604)
22. Katzav A, Chapman J, Shoenfeld Y. CNS dysfunction in the antiphospholipid syndrome. Lupus 12, 903-907 (2003). (Pubitemid 38082085)
23. Karassa FB, Afeltra A, Ambrozic A et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum. 54, 312-324 (2006). (Pubitemid 43122215)
24. Hanly JG, Urowitz MB, Siannis F et al. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum. 58, 843-853 (2008). (Pubitemid 351364883)
25. Degiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 7, 1189-1193 (2001). (Pubitemid 33063773)
26. Arinuma Y, Yanagida T, Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 58, 1130-1135 (2008). (Pubitemid 351564016)
27. Kowal C, Degiorgio LA, Lee JY et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc. Natl Acad. Sci. USA 103, 19854-19859 (2006). (Pubitemid 46037520)
28. Lapteva L, Nowak M, Yarboro CH et al. Anti-N-methyl-d-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum. 54, 2505-2514 (2006). (Pubitemid 44205011)
29. Faust TW, Chang EH, Kowal C et al. Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc. Natl Acad. Sci. USA 107, 18569-18574 (2010).
30. Abbott NJ, Mendonca LL, Dolman DE. The blood-brain barrier in systemic lupus erythematosus. Lupus 12, 908-915 (2003). (Pubitemid 38082086)
31. Davey R, Bamford J, Emery P. The role of endothelial dysfunction in the pathogenesis of neuropsychiatric systemic lupus erythematosus. Lupus 19, 797-802 (2010).
32. Fragoso-Loyo H, Cabiedes J, Orozco-Narvaez A et al. Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis. PLoS ONE 3, e3347 (2008).
33. Banks WA, Erickson MA: The blood-brain barrier and immune function and dysfunction. Neurobiol. Dis. 37, 26-32 (2010).
34. Hawkins BT, Abbruscato TJ, Egleton RD et al. Nicotine increases in vivo blood-brain barrier permeability and alters cerebral microvascular tight junction protein distribution. Brain Res. 1027, 48-58 (2004). (Pubitemid 39370994)
35. Trysberg E, Blennow K, Zachrisson O, Tarkowski A. Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement. Arthritis Res. Ther. 6, R551-R556 (2004).
36. Trysberg E, Carlsten H, Tarkowski A. Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus 9, 498-503 (2000).
37. Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat. Rev. Rheumatol. 6, 358-367 (2010).
38. Karassa FB, Ioannidis JP, Touloumi G, Boki KA, Moutsopoulos HM. Risk factors for central nervous system involvement in systemic lupus erythematosus. QJM 93, 169-174 (2000). (Pubitemid 30128704)
39. Karassa FB, Ioannidis JP, Boki KA et al. Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Am. J. Med. 109, 628-634 (2000).
40. Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology (Oxford) 43, 1555-1560 (2004). (Pubitemid 39642582)
41. Mikdashi J, Krumholz A, Handwerger B. Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology 64, 2102-2107 (2005). (Pubitemid 40881002)
42. Mikdashi J, Handwerger B, Langenberg P, Miller M, Kittner S. Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus. Stroke 38, 281-285 (2007). (Pubitemid 46184295)
43. Tomietto P, Annese V, DAgostini S et al. General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus. Arthritis Rheum. 57, 1461-1472 (2007). (Pubitemid 350308845)
44. Bujan S, Ordi-Ros J, Paredes J et al. Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients. Ann. Rheum. Dis. 62, 859-865 (2003). (Pubitemid 37026497)
45. Andrade RM, Alarcon GS, Gonzalez LA et al. Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). Ann. Rheum. Dis. 67, 829-834 (2008). (Pubitemid 351829384)
46. Padovan M, Castellino G, Bortoluzzi A, Caniatti L, Trotta F, Govoni M. Factors and comorbidities associated with central nervous system involvement in systemic lupus erythematosus: a retrospective cross-sectional case-control study from a single center. Rheumatol. Int. doi: 10.1007/s00296-010-1565 (2010) (Epub ahead of print).
47. Govoni M, Bombardieri S, Bortoluzzi A et al. Factors and comorbidities associated with first central nervous system neuropsychiatric event in systemic lupus erythematosus : does a risk profile exist ? A large multicenter retrospective cross sectional study on 959 italian patients. Rheumatology (Oxford) (2011) (In Press).
48. Chambers SA, Allen E, Rahman A, Isenberg D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford) 48, 673-675 (2009).
49. Fragoso-Loyo HE, Sanchez-Guerrero J. Effect of severe neuropsychiatric manifestations on short-term damage in systemic lupus erythematosus. J. Rheumatol. 34, 76-80 (2007). (Pubitemid 46106566)
50. Alarcon GS, Mcgwin G Jr, Bartolucci AA et al. Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum. 44, 2797-2806 (2001). (Pubitemid 34016199)
51. Cervera R, Abarca-Costalago M, Abramovicz D et al. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the Euro-Lupus Project. Autoimmun. Rev. 5, 180-186 (2006). (Pubitemid 43234182)
52. Petri M. Hopkins Lupus Cohort. 1999 update. Rheum. Dis. Clin. North Am. 26, 199-213 (2000). (Pubitemid 30198756)
53. Gonzalez LA, Pons-Estel GJ, Zhang J, Vila LM, Reveille JD, Alarcon GS. Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort. Lupus 18, 822-830 (2009).
54. Freire EA, Maia IO, Nepomuceno JC, Ciconelli RM. Damage index assessment and quality of life in systemic lupus erythematosus patients (with long-term disease) in Northeastern Brazil. Clin. Rheumatol. 26, 423-428 (2007). (Pubitemid 46486977)
55. Tam LS, Wong A, Mok VC et al. The relationship between neuropsychiatric, clinical, and laboratory variables and quality of life of Chinese patients with systemic lupus erythematosus. J. Rheumatol. 35, 1038-1045 (2008). (Pubitemid 351813149)
56. Hanly JG, Urowitz MB, Su L et al. Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum. 59, 721-729 (2008). (Pubitemid 351679549)
57. Hanly JG, Urowitz MB, Jackson D et al. SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. Ann. Rheum. Dis. 70, 961-967 (2010).
58. Bertsias GK, Ioannidis JP, Aringer M et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann. Rheum. Dis. 69, 2074-2082 (2010).
59. Mosca M, Govoni M, Tomietto P et al. The development of a simple questionnaire to screen patients with SLE for the presence of neuropsychiatric symptoms in routine clinical practice. Lupus 20, 485-492 (2011).
60. Xuan Z, Yi D, Fu-Lin T, Fen-Chun Z. Central nervous system involvement in systemic lupus erythematosus in a hospital-based study of 171 cases: the possible therapeutic role of intrathecal therapy. J. Clin. Rheumatol. 5, 314-319 (1999).
61. Mclean BN, Miller D, Thompson EJ. Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behcets disease involving the nervous system. J. Neurol. Neurosurg. Psychiatry 58, 548-554 (1995).
62. West SG, Emlen W, Wener MH, Kotzin BL. Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am. J. Med. 99, 153-163 (1995).
63. Peterson PL, Axford JS, Isenberg D. Imaging in CNS lupus. Best Pract. Res. Clin. Rheumatol. 19, 727-739 (2005). (Pubitemid 41258580)
64. Cauli A, Montaldo C, Peltz MT et al. Abnormalities of magnetic resonance imaging of the central nervous system in patients with systemic lupus erythematosus correlate with disease severity. Clin. Rheumatol. 13, 615-618 (1994). (Pubitemid 24382798)
65. Jennings JE, Sundgren PC, Attwood J, Mccune J, Maly P. Value of MRI of the brain in patients with systemic lupus erythematosus and neurologic disturbance. Neuroradiology 46, 15-21 (2004). (Pubitemid 38248036)
66. Vermeer SE, Hollander M, Van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 34, 1126-1129 (2003). (Pubitemid 36547501)
67. Petri M, Naqibuddin M, Carson KA et al. Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus. J. Rheumatol. 35, 2348-2354 (2008).
68. Castellino G, Padovan M, Bortoluzzi A et al. Single photon emission computed tomography and magnetic resonance imaging evaluation in SLE patients with and without neuropsychiatric involvement. Rheumatology (Oxford) 47, 319-323 (2008). (Pubitemid 351267199)
69. Sibbitt WL Jr, Sibbitt RR, Brooks WM. Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 42, 2026-2038 (1999). (Pubitemid 30263585)
70. Sibbitt WL Jr, Brooks WM, Kornfeld M, Hart BL, Bankhurst AD, Roldan CA. Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus. Semin. Arthritis Rheum. 40, 32-52 (2011).
71. Appenzeller S, Bonilha L, Rio PA, Min Li L, Costallat LT, Cendes F. Longitudinal analysis of gray and white matter loss in patients with systemic lupus erythematosus. Neuroimage 34, 694-701 (2007). (Pubitemid 44827765)
72. Roldan CA, Gelgand EA, Qualls CR, Sibbitt WL Jr. Valvular heart disease is associated with nonfocal neuropsychiatric systemic lupus erythematosus. J. Clin. Rheumatol. 12, 3-10 (2006). (Pubitemid 44384004)
73. Kozora E, West SG, Kotzin BL, Julian L, Porter S, Bigler E. Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum. 41, 41-47 (1998). (Pubitemid 28041921)
74. Ainiala H, Dastidar P, Loukkola J et al. Cerebral MRI abnormalities and their association with neuropsychiatric manifestations in SLE: a population-based study. Scand. J. Rheumatol. 34, 376-382 (2005). (Pubitemid 41545911)
75. Jung RE, Segall JM, Grazioplene RG, Qualls C, Sibbitt WL, Roldan CA. Cortical thickness and subcortical gray matter reductions in neuropsychiatric systemic lupus erythematosus. PLoS ONE 5, e9302 (2010).
76. Sibbitt WL Jr, Schmidt PJ, Hart BL, Brooks WM. Fluid attenuated inversion recovery (FLAIR) imaging in neuropsychiatric systemic lupus erythematosus. J. Rheumatol. 30, 1983-1989 (2003). (Pubitemid 37075548)
77. Bosma GP, Huizinga TW, Mooijaart SP, Van Buchem MA. Abnormal brain diffusivity in patients with neuropsychiatric systemic lupus erythematosus. AJNR Am. J. Neuroradiol. 24, 850-854 (2003). (Pubitemid 36617414)
78. Welsh RC, Rahbar H, Foerster B, Thurnher M, Sundgren PC. Brain diffusivity in patients with neuropsychiatric systemic lupus erythematosus with new acute neurological symptoms. J. Magn. Reson. Imaging 26, 541-551 (2007). (Pubitemid 350194574)
79. Sibbitt WL Jr, Haseler LJ, Griffey RR, Friedman SD, Brooks WM. Neurometabolism of active neuropsychiatric lupus determined with proton MR spectroscopy. AJNR Am. J. Neuroradiol. 18, 1271-1277 (1997). (Pubitemid 30417707)
80. Axford JS, Howe FA, Heron C, Griffiths JR. Sensitivity of quantitative 1H magnetic resonance spectroscopy of the brain in detecting early neuronal damage in systemic lupus erythematosus. Ann. Rheum. Dis. 60, 106-111 (2001). (Pubitemid 32102199)
81. Brooks WM, Sibbitt WL Jr, Kornfeld M, Jung RE, Bankhurst AD, Roldan CA. The histopathologic associates of neurometabolite abnormalities in fatal neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 62, 2055-2063 (2010).
82. Brooks WM, Jung RE, Ford CC, Greinel EJ, Sibbitt WL Jr. Relationship between neurometabolite derangement and neurocognitive dysfunction in systemic lupus erythematosus. J. Rheumatol. 26, 81-85 (1999). (Pubitemid 29051400)
83. Steens SC, Bosma GP, Steup-Beekman GM, Le Cessie S, Huizinga TW, Van Buchem MA. Association between microscopic brain damage as indicated by magnetization transfer imaging and anticardiolipin antibodies in neuropsychiatric lupus. Arthritis Res. Ther. 8, R38 (2006).
84. Appenzeller S, Li LM, Costallat LT, Cendes F. Neurometabolic changes in normal white matter may predict appearance of hyperintense lesions in systemic lupus erythematosus. Lupus 16, 963-971 (2007).
85. Castellino G, Govoni M, Padovan M, Colamussi P, Borrelli M, Trotta F. Proton magnetic resonance spectroscopy may predict future brain lesions in SLE patients: a functional multi-imaging approach and follow up. Ann. Rheum. Dis. 64, 1022-1027 (2005). (Pubitemid 40909516)
86. Gasparovic CM, Roldan CA, Sibbitt WL Jr et al. Elevated cerebral blood flow and volume in systemic lupus measured by dynamic susceptibility contrast magnetic resonance imaging. J. Rheumatol. 37, 1834-1843 (2010).
87. Lopez-Longo FJ, Carol N, Almoguera MI et al. Cerebral hypoperfusion detected by SPECT in patients with systemic lupus erythematosus is related to clinical activity and cumulative tissue damage. Lupus 12, 813-819 (2003). (Pubitemid 37463097)
88. Oku K, Atsumi T, Furukawa S et al. Cerebral imaging by magnetic resonance imaging and single photon emission computed tomography in systemic lupus erythematosus with central nervous system involvement. Rheumatology (Oxford) 42, 773-777 (2003). (Pubitemid 37220910)
89. Zhang X, Zhu Z, Zhang F, Shu H, Li F, Dong Y. Diagnostic value of single-photon-emission computed tomography in severe central nervous system involvement of systemic lupus erythematosus: a case-control study. Arthritis Rheum. 53, 845-849 (2005). (Pubitemid 41811124)
90. Castellino G, Govoni M, Giacuzzo S, Trotta F. Optimizing clinical monitoring of central nervous system involvement in SLE. Autoimmun. Rev. 7, 297-304 (2008).
91. Roldan CA, Qualls CR, Sopko KS, Sibbitt WL Jr. Transthoracic versus transesophageal echocardiography for detection of Libman-Sacks endocarditis: a randomized controlled study. J. Rheumatol. 35, 224-229 (2008). (Pubitemid 351281142)
92. Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann. Rheum. Dis. 64, 620-625 (2005). (Pubitemid 40469095)
93. Neuwelt CM, Lacks S, Kaye BR, Ellman JB, Borenstein DG. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am. J. Med. 98, 32-41 (1995).
94. Bartolucci P, Brechignac S, Cohen P, Le Guern V, Guillevin L. Adjunctive plasma exchanges to treat neuropsychiatric lupus: a retrospective study on 10 patients. Lupus 16, 817-822 (2007). (Pubitemid 350069795)
95. Neuwelt CM. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther. Apher. Dial. 7, 173-182 (2003). (Pubitemid 36753913)
96. Tokunaga M, Saito K, Kawabata D et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann. Rheum. Dis. 66, 470-475 (2007). (Pubitemid 46580466)
97. Mok CC. Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review. Scand. J. Rheumatol. 36, 329-337 (2007). (Pubitemid 350034802)
98. Milstone AM, Meyers K, Elia J. Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature. Clin. Rheumatol. 24, 394-397 (2005). (Pubitemid 41102439)
99. Sanna G, Bertolaccini ML, Khamashta MA: Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach. Curr. Pharm. Des. 14, 1261-1269 (2008). (Pubitemid 351997820)
100. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N. Engl. J. Med. 332, 993-997 (1995).
101. Tuthill JI, Khamashta MA. Management of antiphospholipid syndrome. J. Autoimmun. 33, 92-98 (2009).
102. Erkan D, Harrison MJ, Levy R et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 56, 2382-2391 (2007). (Pubitemid 47173586)
103. Mitsikostas DD, Sfikakis PP, Goadsby PJ. A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain 127, 1200-1209 (2004). (Pubitemid 38623053)
104. Williams TS, Aranow C, Ross GS et al. Neurocognitive impairment in childhood-onset systemic lupus erythematosus: measurement issues in diagnosis. Arthritis Care Res. (Hoboken) 63(8), 1178-1187 (2011).
105. Kozora E, Hanly JG, Lapteva L, Filley CM. Cognitive dysfunction in systemic lupus erythematosus: past, present, and future. Arthritis Rheum. 58, 3286-3298 (2008).
106. Hanly JG, Cassell K, Fisk JD. Cognitive function in systemic lupus erythematosus: results of a 5-year prospective study. Arthritis Rheum. 40, 1542-1543 (1997). (Pubitemid 27430969)
107. Hanly JG, Omisade A, Su L, Farewell V, Fisk JD. Assessment of cognitive function in systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis by computerized neuropsychological tests. Arthritis Rheum. 62, 1478-1486 (2010).
108. Denburg SD, Carbotte RM, Denburg JA. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum. 37, 1311-1320 (1994). (Pubitemid 24320748)
109. Hanly JG, Hong C, Smith S, Fisk JD. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum. 42, 728-734 (1999). (Pubitemid 29171993)
110. Mclaurin EY, Holliday SL, Williams P, Brey RL. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 64, 297-303 (2005).
111. Harrison MJ, Morris KA, Horton R et al. Results of intervention for lupus patients with self-perceived cognitive difficulties. Neurology 65, 1325-1327 (2005). (Pubitemid 41508241)
112. Bernatsky S, Clarke A, Gladman DD et al. Mortality related to cerebrovascular disease in systemic lupus erythematosus. Lupus 15, 835-839 (2006). (Pubitemid 46044915)
113. Khamashta MA, Hunt BJ. Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No. J. Thromb. Haemost. 3, 844-845 (2005). (Pubitemid 41632806)
114. Kur JK, Esdaile JM. Posterior reversible encephalopathy syndrome -an underrecognized manifestation of systemic lupus erythematosus. J. Rheumatol. 33, 2178-2183 (2006). (Pubitemid 44749776)
115. Leroux G, Sellam J, Costedoat-Chalumeau N et al. Posterior reversible encephalopathy syndrome during systemic lupus erythematosus: four new cases and review of the literature. Lupus 17, 139-147 (2008). (Pubitemid 351346449)
116. Chen HA, Lin YJ, Chen PC, Chen TY, Lin KC, Cheng HH. Systemic lupus erythematosus complicated with posterior reversible encephalopathy syndrome and intracranial vasculopathy. Int. J. Rheum. Dis. 13, e79-e82 (2010).
117. Pego-Reigosa JM, Isenberg DA. Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology (Oxford) 47, 1498-1502 (2008).
118. Espinosa G, Mendizabal A, Minguez S et al. Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. Semin. Arthritis Rheum. 39, 246-256 (2010).
119. DCruz DP, Mellor-Pita S, Joven B et al. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J. Rheumatol. 31, 280-285 (2004). (Pubitemid 38160749)
120. Birnbaum J, Petri M, Thompson R, Izbudak I, Kerr D. Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum. 60, 3378-3387 (2009).
121. Matiello M, Jacob A, Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr. Opin. Neurol. 20, 255-260 (2007). (Pubitemid 46743105)
122. Frohman EM, Wingerchuk DM. Clinical practice. Transverse myelitis. N. Engl. J. Med. 363, 564-572 (2010).
123. Ye Y, Qian J, Gu Y, Chen X, Ye S. Rituximab in the treatment of severe lupus myelopathy. Clin. Rheumatol. 30, 981-986 (2011).
124. Katsiari CG, Giavri I, Mitsikostas DD, Yiannopoulou KG, Sfikakis PP. Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation. Eur. J. Neurol. 18, 556-563 (2011).
125. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 60, 3761-3765 (2009).
126. Itoh K, Kano T, Nagashio C, Mimori A, Kinoshita M, Sumiya M. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus. Arthritis Rheum. 54, 1020-1022 (2006).
127. Ferreira S, DCruz DP, Hughes GR. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology (Oxford) 44, 434-442 (2005). (Pubitemid 41511130)
128. Brey RL, Petri MA. Neuropsychiatric systemic lupus erythematosus: miles to go before we sleep. Neurology 61, 9-10 (2003). (Pubitemid 36818738)
129. Govoni M, Farina I, Bortoluzzi A et al. Attribution of neuropsychiatric events in SLE: validation of an algoythm on an external multicenter cohort. Presented at: EULAR 2010. Rome, Italy, 16-19 June 2010.
130. Difrancesco MW, Holland SK, Ris MD et al. Functional magnetic resonance imaging assessment of cognitive function in childhood-onset systemic lupus erythematosus: a pilot study. Arthritis Rheum. 56, 4151-4163 (2007). (Pubitemid 350262343)
131. Jung RE, Caprihan A, Chavez RS et al. Diffusion tensor imaging in neuropsychiatric systemic lupus erythematosus. BMC Neurol. 10, 65 (2010).
132. Ramage AE, Fox PT, Brey RL et al. Neuroimaging evidence of white matter inflammation in newly diagnosed systemic lupus erythematosus. Arthritis Rheum. doi: 10.1002/art.30458 (2011) (Epub ahead of print).
133. Mathieu A, Vacca A, Serra A et al. Defective cerebral g-aminobutyric acid-A receptor density in patients with systemic lupus erythematosus and central nervous system involvement. An observational study. Lupus 19, 918-926 (2010).
134. Blank M, Beinglass I, Shoenfeld Y. The therapeutic potential of targeting anti-Ribosomal-P antibody in treating SLE patients with depression. Expert Opin. Biol. Ther. 7, 1283-1285 (2007). (Pubitemid 47475649)
135. Diamond B, Bloom O, Al Abed Y, Kowal C, Huerta PT, Volpe BT. Moving towards a cure: blocking pathogenic antibodies in systemic lupus erythematosus. J. Intern. Med. 269, 36-44 (2011).
136. Bloom O, Cheng KF, He M et al. Generation of a unique small molecule peptidomimetic that neutralizes lupus autoantibody activity. Proc. Natl Acad. Sci. USA 108, 10255-10259 (2011).